As well as contributing to recurrent vasoconstriction and hypertension, BRAF inhibitor/MEK inhibitor–related reductions in NO bioavailability also lead to an imbalance between thrombotic and antithrombotic states and may result in thrombotic sequelae. This evidence concerns the gene BRAF and Hypertension.